Asian Spectator

Men's Weekly

.

Ice and Snow as a Bridge to Global Dialogue, Charting a New Chapter of Cooperative Development: the Global Mayors Dialogue · Harbin Kicked Off on January 6

HARBIN, CHINA - Media OutReach Newswire - 6 January 2026 - Using the city as a window to showcase China's opportunities and mayors as catalysts for exchanging governance insights, the "Global Mayors ...

Carlsberg Asia and Meituan Elevate Strategic Partnership with First-Time Black Pearl Collaboration

From premium dining collaborations to seamless quick‑commerce, Carlsberg Asia is ushering a new era of beer enjoyment in AsiaHONG KONG SAR - Media OutReach Newswire - 11 December 2025...

Digital Longhua Supports a Spectacular Model (Aviation) Sport Competition of the 15th NG Mass Participation Events

SHENZHEN, CHINA - Media OutReach Newswire - 31 October 2025 - In recent days, the Model (Aviation) Sport of the Mass Participation Events of the 15th National Games (NG) of China has held i...

TDCX the first Southeast Asian and Singapore-headquartered service provider to be recognized among world's top outsourcing companies

TDCX ranked 18th in OA500 Index which recognizes top BPO firms globallySINGAPORE - Media OutReach Newswire - 11 April 2024 - TDCX, an award-winning digital customer experience (CX) solution...

Taiwan, Florida cities deploy AI to address rising urbanization challenges

TAIPEI, TAIWAN - Media-OutReach Newswire - 18 November 2025 - In Taoyuan's traffic control center, dozens of monitors display green lights cascading through city streets. When an ambulance ...

Bitpanda Launches their Global Exchange After Having Raised 43...

VIENNA, Aug. 7, 2019 /PRNewswire-AsiaNet/ -- - Bitpanda raised 43.6 million Euros by selling out their IEO- BEST is the most successful European IEO to date- The Bitpanda Global Exchange is ...

Guotai Junan finalizes first QFII margin trading stock borro...

SHANGHAI, Dec. 31, 2020 /Xinhua-AsiaNet/-- Guotai Junan Securities facilitated a qualified foreign institutional investor (QFII) to finalize its first margin trading and stock borrowing and ...

Conscience over coercion: The Asian Vision Institute calls on ...

PHNOM PENH, Cambodia, Oct. 11, 2019 /PRNewswire-AsiaNet/ -- Officials from the European Commission and the European External Action Service are assessing Cambodia's standing in the Everythin...

Edge Healthcare Unveils a New Series of Evidence-Based Care and Multidisciplinary Approach catering to Pains and Aches

SINGAPORE - Media OutReach - 5 October 2023- Edge Healthcare, an osteopathy and physiotherapy clinic in Singapore, has unveiled a comprehensive series of holistic, evidence-based care serv...

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

SYDNEY, Apr 8, 2020 - (ACN Newswire) - Asia-Pacific's largest specialist biotech CRO Novotech said the top 10 biotech sites in Australia were open for clinical trial activity with many sites modifying their practices to ensure continuity of operations.

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

View and Download the COVID-19 Australia Data Bulletin here. https://novotech-cro.com/covid-19-notice

The data is part of a new series prepared for Novotech clients detailing the current status of trials in the Asia-Pacific during the global COVID-19 crisis.

Novotech CEO Dr John Moller said the Bulletin series taps local knowledge of fundamentals in the sector and shows which countries in the region are able to support clinical research for Novotech and its clients during this time.

"While the situation is always evolving, Australia appears to be managing the crisis well. Our sites have changed how they manage trials in line with Australian Government health guidelines and most are still able to deliver the clinical trial services we need for our clients," said Dr Moller. "Study delays caused by COVID-19 can be rapidly addressed by activating new sites in Australia and Asia."

Australia has attractive start-up times, world leading investigators and research teams, and valuable rebates of up to 43.5% on clinical trial spend.

About Novotech

Novotech, established in 1996, is internationally recognized as the leading full-service contract research organization (CRO) in Asia-Pacific. Novotech provides clinical development services across all clinical trial phases and therapeutic areas and has been instrumental in the success of over a thousand Phase I - IV clinical trials for biotech companies.

Novotech obtained the ISO 27001, the best-known standard in the ISO family, providing the requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies. Visit http://novotech-cro.com.

For RFP enquiries: Please fill out the form available at https://novotech-cro.com/talk-to-an-expert

Media ContactSusan Fitzpatrick-Napiercommunications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Negara minta guru jadi konselor: Tak adil bagi guru, tak aman buat siswa

● Menjadikan guru sebagai konselor berisiko membebani guru, mengaburkan peran profesional, dan mengancam keselamatan siswa.● Peran konseling memerlukan keahlian khusus.● Deteksi dini...

‘Gene editing’ di Indonesia: Bisakah bioteknologi baru menjawab masalah klasik pertanian?

● Teknologi gene editing menawarkan peluang meningkatkan kualitas tanaman tanpa menambah gen asing. ● Namun, masalah pertanian sesungguhnya adalah ketimpangan akses lahan, modal, benih, da...

Mengungkap kapal-kapal gelap: Cerita dari laut dan mereka yang terdampak

Penangkapan ikan ilegal kian menyerupai bayangan besar yang menutupi lautan kita. Kapal-kapal gelap memasuki perairan berbagai negara untuk menjarah ikan, sering kali dengan mematikan transponder agar...